Complement Is a Central Mediator of Radiotherapy-Induced Tumor-Specific Immunity and Clinical Response

Immunity

Volumn 42, Issue 4, 2015, Pages 767-777

  Surace, Laura ^a   Lysenko, Veronika ^a   Fontana, Andrea Orlando ^b   Cecconi, Virginia ^a   Janssen, Hans ^c   Bicvic, Antonela ^a   Okoniewski, Michal ^d   Pruschy, Martin ^b   Dummer, Reinhard ^e   Neefjes, Jacques ^c   Knuth, Alexander ^b,f   Gupta, Anurag ^a   van den Broek, Maries ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d ETH ZURICH   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; DEXAMETHASONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; COMPLEMENT RECEPTOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ARTICLE; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELL DEATH; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR CELL; UPREGULATION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GAMMA RADIATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; MELANOMA, EXPERIMENTAL; PATHOLOGY; RADIATION RESPONSE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; COMPLEMENT ACTIVATION; COMPLEMENT C3A; COMPLEMENT C5A; DEXAMETHASONE; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, INNATE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, COMPLEMENT; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 84928205744     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2015.03.009     Document Type: Article

References (66)

1. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
2. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995, 270:286-290.
3. Baelder R., Fuchs B., Bautsch W., Zwirner J., Köhl J., Hoymann H.G., Glaab T., Erpenbeck V., Krug N., Braun A. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J.Immunol. 2005, 174:783-789.
4. Basu S., Binder R.J., Suto R., Anderson K.M., Srivastava P.K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 2000, 12:1539-1546.
5. Baudino L., Sardini A., Ruseva M.M., Fossati-Jimack L., Cook H.T., Scott D., Simpson E., Botto M. C3 opsonization regulates endocytic handling of apoptotic cells resulting in enhanced T-cell responses to cargo-derived antigens. Proc. Natl. Acad. Sci. USA 2014, 111:1503-1508.
6. Burnette B.C., Liang H., Lee Y., Chlewicki L., Khodarev N.N., Weichselbaum R.R., Fu Y.X., Auh S.L. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 2011, 71:2488-2496.
7. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
8. Chen G., Tan C.S., Teh B.K., Lu J. Molecular mechanisms for synchronized transcription of three complement C1q subunit genes in dendritic cells and macrophages. J.Biol. Chem. 2011, 286:34941-34950.
9. Ciurana C.L., Zwart B., van Mierlo G., Hack C.E. Complement activation by necrotic cells in normal plasma environment compares to that by late apoptotic cells and involves predominantly IgM. Eur. J. Immunol. 2004, 34:2609-2619.
10. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006, 6:836-848.
11. Elvington M., Scheiber M., Yang X., Lyons K., Jacqmin D., Wadsworth C., Marshall D., Vanek K., Tomlinson S. Complement-dependent modulation of antitumor immunity following radiation therapy. Cell Rep. 2014, 8:818-830.
12. Engelman R.M., Rousou J.A., Flack J.E., Deaton D.W., Kalfin R., Das D.K. Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. Ann. Thorac. Surg. 1995, 60:801-804.
13. Eriksson D., Stigbrand T. Radiation-induced cell death mechanisms. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2010, 31:363-372.
14. Farrar C.A., Sacks S.H. Mechanisms of rejection: role of complement. Curr. Opin. Organ Transplant. 2014, 19:8-13.
15. Favaudon V., Caplier L., Monceau V., Pouzoulet F., Sayarath M., Fouillade C., Poupon M.F., Brito I., Hupe P., Bourhis J., et al. Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice. Science translational medicine 2014, 6:245ra293.
16. Formenti S.C., Demaria S. Radiation therapy to convert the tumor into an insitu vaccine. Int. J. Radiat. Oncol. Biol. Phys. 2012, 84:879-880.
17. Fridman W.H., Galon J., Pagès F., Tartour E., Sautès-Fridman C., Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011, 71:5601-5605.
18. Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host type I IFN signals are required for antitumor CD8+ Tcell responses through CD8alpha+ dendritic cells. J.Exp. Med. 2011, 208:2005-2016.
19. Fukuoka Y., Hite M.R., Dellinger A.L., Schwartz L.B. Human skin mast cells express complement factors C3 and C5. J.Immunol. 2013, 191:1827-1834.
20. Godau J., Heller T., Hawlisch H., Trappe M., Howells E., Best J., Zwirner J., Verbeek J.S., Hogarth P.M., Gerard C., et al. C5a initiates the inflammatory cascade in immune complex peritonitis. J.Immunol. 2004, 173:3437-3445.
21. Gupta A., Probst H.C., Vuong V., Landshammer A., Muth S., Yagita H., Schwendener R., Pruschy M., Knuth A., van den Broek M. Radiotherapy promotes tumor-specific effector CD8+ Tcells via dendritic cell activation. J.Immunol. 2012, 189:558-566.
22. Hasegawa M., Yada S., Liu M.Z., Kamada N., Muñoz-Planillo R., Do N., Núñez G., Inohara N. Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage. Immunity 2014, 41:620-632.
23. Hempen C., Weiss E., Hess C.F. Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects?. Support. Care Cancer 2002, 10:322-328.
24. Huang Y., Krein P.M., Muruve D.A., Winston B.W. Complement factor B gene regulation: synergistic effects of TNF-alpha and IFN-gamma in macrophages. J.Immunol. 2002, 169:2627-2635.
25. Hughes M.A., Parisi M., Grossman S., Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62:1423-1426.
26. Keller A.M., Schildknecht A., Xiao Y., van den Broek M., Borst J. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ Tcell tolerance and permits effective immunity. Immunity 2008, 29:934-946.
27. Kemper C., Mitchell L.M., Zhang L., Hourcade D.E. The complement protein properdin binds apoptotic Tcells and promotes complement activation and phagocytosis. Proc. Natl. Acad. Sci. USA 2008, 105:9023-9028.
28. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
29. Kolev M., Towner L., Donev R. Complement in cancer and cancer immunotherapy. Arch. Immunol. Ther. Exp. (Warsz.) 2011, 59:407-419.
30. Kolev M., Le Friec G., Kemper C. Complement-tapping into new sites and effector systems. Nat. Rev. Immunol. 2014, 14:811-820.
31. Kopf M., Abel B., Gallimore A., Carroll M., Bachmann M.F. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat. Med. 2002, 8:373-378.
32. Lalli P.N., Strainic M.G., Lin F., Medof M.E., Heeger P.S. Decay accelerating factor can control Tcell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production. J.Immunol. 2007, 179:5793-5802.
33. Li K., Sacks S.H., Zhou W. The relative importance of local and systemic complement production in ischaemia, transplantation and other pathologies. Mol. Immunol. 2007, 44:3866-3874.
34. Liszewski M.K., Kolev M., Le Friec G., Leung M., Bertram P.G., Fara A.F., Subias M., Pickering M.C., Drouet C., Meri S., et al. Intracellular complement activation sustains Tcell homeostasis and mediates effector differentiation. Immunity 2013, 39:1143-1157.
35. Liu F., Whitton J.L. Cutting edge: re-evaluating the invivo cytokine responses of CD8+ Tcells during primary and secondary viral infections. J.Immunol. 2005, 174:5936-5940.
36. Liu J., Lin F., Strainic M.G., An F., Miller R.H., Altuntas C.Z., Heeger P.S., Tuohy V.K., Medof M.E. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J.Immunol. 2008, 180:5882-5889.
37. Lugade A.A., Moran J.P., Gerber S.A., Rose R.C., Frelinger J.G., Lord E.M. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J.Immunol. 2005, 174:7516-7523.
38. Ma Y., Kepp O., Ghiringhelli F., Apetoh L., Aymeric L., Locher C., Tesniere A., Martins I., Ly A., Haynes N.M., et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin. Immunol. 2010, 22:113-124.
39. Markiewski M.M., Lambris J.D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 2007, 171:715-727.
40. Markiewski M.M., Lambris J.D. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 2009, 30:286-292.
41. Markiewski M.M., DeAngelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard C., Coukos G., Lambris J.D. Modulation of the antitumor immune response by complement. Nat. Immunol. 2008, 9:1225-1235.
42. Matsumura S., Wang B., Kawashima N., Braunstein S., Badura M., Cameron T.O., Babb J.S., Schneider R.J., Formenti S.C., Dustin M.L., Demaria S. Radiation-induced CXCL16 release by breast cancer cells attracts effector Tcells. J.Immunol. 2008, 181:3099-3107.
43. McDermott D.F., Atkins M.B. PD-1 as a potential target in cancer therapy. Cancer Med 2013, 2:662-673.
44. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
45. Merrick A., Errington F., Milward K., O'Donnell D., Harrington K., Bateman A., Pandha H., Vile R., Morrison E., Selby P., Melcher A. Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. Br. J. Cancer 2005, 92:1450-1458.
46. Packard B.D., Weiler J.M. Steroids inhibit activation of the alternative-amplification pathway of complement. Infect. Immun. 1983, 40:1011-1014.
47. Peng Q., Li K., Wang N., Li Q., Asgari E., Lu B., Woodruff T.M., Sacks S.H., Zhou W. Dendritic cell function in allostimulation is modulated by C5aR signaling. J.Immunol. 2009, 183:6058-6068.
48. Pio R., Corrales L., Lambris J.D. The role of complement in tumor growth. Adv. Exp. Med. Biol. 2014, 772:229-262.
49. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., Mu Z., Rasalan T., Adamow M., Ritter E., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N.Engl. J. Med. 2012, 366:925-931.
50. Prise K.M., O'Sullivan J.M. Radiation-induced bystander signalling in cancer therapy. Nat. Rev. Cancer 2009, 9:351-360.
51. Probst H.C., Lagnel J., Kollias G., van den Broek M. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ Tcell tolerance. Immunity 2003, 18:713-720.
52. Qing X., Koo G.C., Salmon J.E. Complement regulates conventional DC-mediated NK-cell activation by inducing TGF-β1 in Gr-1+ myeloid cells. Eur. J. Immunol. 2012, 42:1723-1734.
53. Quartier P., Potter P.K., Ehrenstein M.R., Walport M.J., Botto M. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages invitro. Eur. J. Immunol. 2005, 35:252-260.
54. Reits E.A., Hodge J.W., Herberts C.A., Groothuis T.A., Chakraborty M., Wansley E.K., Camphausen K., Luiten R.M., de Ru A.H., Neijssen J., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J.Exp. Med. 2006, 203:1259-1271.
55. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
56. Roumenina L.T., Sène D., Radanova M., Blouin J., Halbwachs-Mecarelli L., Dragon-Durey M.A., Fridman W.H., Fremeaux-Bacchi V. Functional complement C1q abnormality leads to impaired immune complexes and apoptotic cell clearance. J.Immunol. 2011, 187:4369-4373.
57. Schmudde I., Laumonnier Y., Köhl J. Anaphylatoxins coordinate innate and adaptive immune responses in allergic asthma. Semin. Immunol. 2013, 25:2-11.
58. Schonthaler H.B., Guinea-Viniegra J., Wculek S.K., Ruppen I., Ximénez-Embún P., Guío-Carrión A., Navarro R., Hogg N., Ashman K., Wagner E.F. S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3. Immunity 2013, 39:1171-1181.
59. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
60. Sharma A., Bode B., Studer G., Moch H., Okoniewski M., Knuth A., von Boehmer L., van den Broek M. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. Clinical cancer research: an official journal of the American Association for Cancer Research 2013, 19:4843-4853.
61. Strainic M.G., Liu J., Huang D., An F., Lalli P.N., Muqim N., Shapiro V.S., Dubyak G.R., Heeger P.S., Medof M.E. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ Tcells. Immunity 2008, 28:425-435.
62. + regulatory Tcells. Nat. Immunol. 2013, 14:162-171.
63. Sun S., Guo Y., Zhao G., Zhou X., Li J., Hu J., Yu H., Chen Y., Song H., Qiao F., et al. Complement and the alternative pathway play an important role in LPS/D-GalN-induced fulminant hepatic failure. PLoS ONE 2011, 6:e26838.
64. Takeshima T., Chamoto K., Wakita D., Ohkuri T., Togashi Y., Shirato H., Kitamura H., Nishimura T. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 2010, 70:2697-2706.
65. Verbrugge I., Gasparini A., Haynes N.M., Hagekyriakou J., Galli M., Stewart T.J., Abrams S.I., Yagita H., Verheij M., Johnstone R.W., et al. The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling. Radiat. Res. 2014, 182:219-229.
66. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008, 27:6207-6215.